JGH Open最新文献

{"title":"Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection-Site Reactions.","authors":"Makoto Furuya, Kiichiro Yoza, Takeshi Yonezawa, Ken Takeuchi","doi":"10.1002/jgh3.70407","DOIUrl":"10.1002/jgh3.70407","url":null,"abstract":"<p><strong>Background/aims: </strong>The subcutaneous (SC) formulation of vedolizumab is available as an alternative to the intravenous (IV) formulation in patients with ulcerative colitis (UC). However, data from Asian patients are limited, and the clinical course of injection-site reactions (ISRs) remains unclear. This study evaluated the efficacy and safety of switching from IV to SC vedolizumab in Japanese patients with UC, focusing on ISRs.</p><p><strong>Methods: </strong>This retrospective study included patients who switched from IV to SC vedolizumab. The primary outcomes were the incidence and clinical course of ISRs. The secondary outcomes included adverse events other than ISRs, disease activity, remission rates, and treatment persistence.</p><p><strong>Results: </strong>In total, 48 patients were included. The median fecal calprotectin levels remained stable from baseline to 12 months after switching (46.0 vs. 46.0 μg/g), with the fecal calprotectin remission rate remaining stable (41/45, 91% vs. 39/45, 87%). The persistence rate of SC vedolizumab was 98%, and the persistence rate without additional therapy was 94%. ISRs occurred in 29 patients (60%), most frequently within 3-6 months, with a median duration of 4 months. More than half of ISRs improved or resolved by 12 months, and only 11 patients (23%) experienced persistent ISRs. No adverse events other than ISRs were considered likely or probably related to SC vedolizumab.</p><p><strong>Conclusions: </strong>In Asian patients with UC, disease activity was maintained after switching from IV to SC vedolizumab. Although ISRs were common after switching, most were self-limiting. Therefore, switching back to IV formulation solely for ISR management should be cautiously considered.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":"e70407"},"PeriodicalIF":1.6,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147784904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148086436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stricturing Diseases of the Gastrointestinal Tract-Current Clinical Practice.","authors":"Monjur Ahmed","doi":"10.1002/jgh3.70411","DOIUrl":"10.1002/jgh3.70411","url":null,"abstract":"<p><p>Gastrointestinal stricture can occur in the esophagus, stomach, small intestine, colon, and anorectum. Most of the strictures are benign. The prevalence of esophageal strictures (ES) secondary to eosinophilic esophagitis has increased. Pyloric stenosis (PS) is rarely seen in clinical practice. Sleeve stenosis (SS) and stomal stenosis or gastrojejunal anastomotic stricture (GJAS) are increasingly seen due to bariatric surgery. Crohn's disease (CD) remains a significant challenge even in the biologic era. The symptomatology of strictures depends on the location, severity, and underlying cause. Imaging studies and endoscopic procedures are the primary investigations to diagnose and evaluate strictures. Various treatment modalities are available to treat gastrointestinal strictures. Successful stricture treatment can significantly improve a patient's quality of life. Benign strictures carry a much better prognosis than malignant strictures. Multiple other factors influence response to treatment.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 ","pages":"e70411"},"PeriodicalIF":1.6,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147784874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148086435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148081385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148081452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148081453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Cholecystectomy After Acute Biliary Severe Pancreatitis: A Systematic Review-Time for A Clinical Trial?","authors":"Carlos Eduardo Rey Chaves, Juan Pablo Diaz Amarís, Maria Alejandra Diaz Tarazona, Laura Sarmiento, Danny Conde, Isabella Alarcón, David Gómez Garnica","doi":"10.1002/jgh3.70368","DOIUrl":"10.1002/jgh3.70368","url":null,"abstract":"<p><strong>Background: </strong>There is a lack of evidence about the optimal timing for cholecystectomy in patients with severe acute pancreatitis. The discussion centers on evaluating the benefits of performing early versus delayed cholecystectomy, looking for better outcomes. This systematic review aimed to assess the postoperative outcomes after cholecystectomy in patients with severe pancreatitis regarding the timing of the surgery.</p><p><strong>Methods: </strong>A systematic review was conducted, and the inclusion criteria included original, peer-reviewed retrospective or prospective studies involving humans > 18 years old with acute severe pancreatitis due to gallstone disease who underwent laparoscopic cholecystectomy. Newcastle Ottawa score was used to perform quality and bias assessment. The search was conducted from January 2004 to December 2023 within Pubmed, EMBASE, and Scopus.</p><p><strong>Results: </strong>A total of 1198 studies were found; after screening for duplicates, eligibility criteria and conducting quality assessment, three articles met the inclusion criteria and were included in the systematic review, involving a total of 598 patients. Early cholecystectomy (Defined < 15 days or 6 weeks) was performed in 30.10% (<i>n</i> = 179) and delayed cholecystectomy in 70.06% (<i>n</i> = 419), with a morbidity rate of 33% (<i>n</i> = 60) and 20% (<i>n</i> = 86), respectively. Mortality was most frequent when cholecystectomy was performed earlier (2.39% <i>n</i> = 10 vs. 0.23% <i>n</i> = 1).</p><p><strong>Conclusion: </strong>Despite limitations regarding the small sample size and the small amount of research published to date, this systematic review suggests that there is a higher risk of morbidity and mortality in patients with severe pancreatitis undergoing early cholecystectomy compared to those undergoing delayed cholecystectomy.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":"e70368"},"PeriodicalIF":1.6,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13090528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tegoprazan in Gastroesophageal Reflux Disease and Related Acid-Mediated Conditions: A Systematic Review and Meta-Analysis.","authors":"Sanjay Bandyopadhyay, Mahesh Goenka, Debapratim Routh, G N Ramesh, Parimal Lawate","doi":"10.1002/jgh3.70406","DOIUrl":"10.1002/jgh3.70406","url":null,"abstract":"<p><p>Gastroesophageal reflux disease (GERD) is a chronic relapsing disorder often inadequately controlled with proton pump inhibitors (PPIs), particularly in patients with nocturnal acid breakthrough (NAB) or non-erosive reflux disease (NERD). Tegoprazan, a potassium-competitive acid blocker (PCAB), offers rapid, potent, and CYP2C19-independent acid suppression. This systematic review and meta-analysis evaluated randomized controlled trials comparing Tegoprazan with PPIs in adults with GERD and related disorders. Databases searched included PubMed, Cochrane, Wiley, and ClinicalTrials.gov (2015-2026). Eighteen studies met inclusion criteria. In erosive esophagitis, Tegoprazan 50 mg once daily achieved mucosal healing rates of 91.1%-99.1%, non-inferior to PPIs (93.5%-98.9%; pooled RR = 1.01, 95% CI 0.98-1.05). Pharmacodynamic and clinical studies demonstrated faster acid suppression and improved nocturnal pH control versus PPIs, achieving pH ≥ 4 within 30-60 min and maintaining levels throughout the 12-h period. In nocturnal symptom analyses, Tegoprazan achieved earlier relief (1.5 vs. 3 days to first heartburn-free night) and higher proportions of heartburn-free nights (57.8% vs. 43.1%), with significantly greater complete (<i>p</i> = 0.038) and partial (<i>p</i> = 0.034) nighttime symptom resolution than Esomeprazole. In NERD, symptom resolution ranged from 42.5% to 48.9% versus 24.2% with placebo. In open-label functional dyspepsia cohorts, improvements ranged from 74.6% to 86.7% in open-label cohorts. Seven trials (<i>n</i> = 2492) showed higher <i>Helicobacter pylori</i> eradication with Tegoprazan-based therapy (RR = 1.05, 95% CI 1.01-1.09; <i>p</i> = 0.006; <i>I</i> ² = 0%). Adverse events were mild and comparable to PPIs. Tegoprazan provides rapid, sustained acid suppression, effective nocturnal symptom control, and a modest but statistically significant improvement in <i>H. pylori</i> eradication, representing a potential alternative to PPIs for patients with persistent or CYP2C19-related variable response.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":"e70406"},"PeriodicalIF":1.6,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13090113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147723885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148081689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}